ERBB2 and breast cancer: In summary, based exclusively on clinical characteristics, one cannot identify a subgroup of the HR+ HER2-negative advanced BC patient subgroup that does not derive benefit from the addition of a CDK4/6 inhibitor to endocrine therapy, both in the resistance and sensitivity hormone setting.